Dogwood Therapeutics, Inc. annual report, FY2023

Business context and reporting period

This summary covers the Form 10-K for the fiscal year ended December 31, 2023. The filing is for Virios Therapeutics, Inc. (Nasdaq: VIRI), not Dogwood Therapeutics, Inc.; verify that this is the intended filing. Virios is a pre-revenue, development-stage biotechnology company developing IMC-1 for fibromyalgia and IMC-2 for Long-COVID.

Financial results and liquidity

At year-end 2023, cash was $3.32 million, current assets were $4.17 million, current liabilities were $0.36 million, and stockholders’ equity was $3.81 million. The company had no debt outstanding. Interest income was $151,000. Profit margins are not applicable because the company had no revenue and incurred operating losses.

Material changes versus 2022

Net loss narrowed by $6.95 million, primarily as research and development spending fell by $6.34 million following completion of major fibromyalgia trial and toxicology work. Operating cash use declined by $6.60 million. Cash fell by $3.71 million to $3.32 million. Financing provided $1.16 million in 2023 through an at-the-market stock sale, versus $4.49 million from a public offering in 2022. The ATM agreement was terminated in September 2023.

Outlook, risks and unusual items

• Going concern and funding: Management says year-end cash is insufficient for at least the next 12 months and that additional capital is needed within six to eight months. The auditor’s report highlights substantial doubt about the company’s ability to continue as a going concern. The company has no committed external funding source; failure to raise capital could delay or curtail programs.
• IMC-1: The Phase 2b FORTRESS trial did not meet its prespecified primary endpoint overall (p=0.302). Company-reported subgroup and post-hoc analyses found improvement among “new” patients and in the later-enrolled cohort; these analyses do not change the failed overall primary endpoint. FDA has agreed to the proposed Phase 3 program, but the company is exploring partnerships as its primary path to fund it. IMC-1 has FDA Fast Track designation.
• IMC-2: An exploratory, open-label Long-COVID study reported symptom improvements, but its design and small treated cohort limit the strength of the evidence. A randomized, double-blind, placebo-controlled investigator-sponsored study began enrollment in December 2023, with results expected in the second half of 2024. The company targets a Phase 2 Long-COVID trial in the second half of 2024, contingent on funding.
• Other risks: Both candidates remain investigational, with clinical, regulatory, manufacturing, intellectual-property, reimbursement and commercialization risks. The company relies on third-party manufacturers and clinical research providers and had four full-time employees at year-end.
• Nasdaq listing: The company received a notice in November 2023 for trading below Nasdaq’s $1.00 minimum bid price for 30 consecutive business days. The initial compliance deadline was May 1, 2024; the filing provides no later outcome.
• Subsequent event: In February 2024, the board approved salary reductions for employees and fee reductions for non-executive directors effective March 1, alongside stock-option grants.
• Controls and legal matters: Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal-control effectiveness. The filing reports no material pending litigation.

Most important facts for investors to verify

• Confirm the issuer identity: this filing is for Virios Therapeutics, not Dogwood Therapeutics.
• Check the company’s current cash, financing status and runway against the stated need to raise capital within six to eight months.
• Verify subsequent clinical updates, especially the randomized IMC-2 study results and whether the planned Phase 2 trial began.
• Assess the full FORTRESS results and distinguish the failed primary endpoint from post-hoc subgroup findings.
• Check Nasdaq’s current listing status and any subsequent capital raises, dilution, or partnership agreements.